Literature DB >> 28371598

Natural and Chemotherapy-Induced Clonal Evolution of Tumors.

M K Ibragimova1, M M Tsyganov, N V Litviakov.   

Abstract

Evolution and natural selection of tumoral clones in the process of transformation and the following carcinogenesis can be called natural clonal evolution. Its main driving factors are internal: genetic instability initiated by driver mutations and microenvironment, which enables selective pressure while forming the environment for cell transformation and their survival. We present our overview of contemporary research dealing with mechanisms of carcinogenesis in different localizations from precancerous pathologies to metastasis and relapse. It shows that natural clonal evolution establishes intratumoral heterogeneity and enables tumor progression. Tumors of monoclonal origin are of low-level intratumoral heterogeneity in the initial stages, and this increases with the size of the tumor. Tumors of polyclonal origin are of extremely high-level intratumoral heterogeneity in the initial stages and become more homogeneous when larger due to clonal expansion. In cases of chemotherapy-induced clonal evolution of a tumor, chemotherapy becomes the leading factor in treatment. The latest research shows that the impact of chemotherapy can radically increase the speed of clonal evolution and lead to new malignant and resistant clones that cause tumor metastasis. Another option of chemotherapy-induced clonal evolution is formation of a new dominant clone from a clone that was minor in the initial tumor and obtained free space due to elimination of sensitive clones by chemotherapy. As a result, in ~20% of cases, chemotherapy can stimulate metastasis and relapse of tumors due to clonal evolution. The conclusion of the overview formulates approaches to tumor treatment based on clonal evolution: in particular, precision therapy, prediction of metastasis stimulation in patients treated with chemotherapy, methods of genetic evaluation of chemotherapy efficiency and clonal-oriented treatment, and approaches to manipulating the clonal evolution of tumors are presented.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28371598     DOI: 10.1134/S0006297917040022

Source DB:  PubMed          Journal:  Biochemistry (Mosc)        ISSN: 0006-2979            Impact factor:   2.487


  13 in total

Review 1.  Chemotherapy-induced metastasis: mechanisms and translational opportunities.

Authors:  George S Karagiannis; John S Condeelis; Maja H Oktay
Journal:  Clin Exp Metastasis       Date:  2018-01-06       Impact factor: 5.150

2.  Tumor immunotherapy: New aspects of natural killer cells.

Authors:  Yangxi Li; Rui Sun
Journal:  Chin J Cancer Res       Date:  2018-04       Impact factor: 5.087

Review 3.  DNA Damage/Repair Management in Cancers.

Authors:  Jehad F Alhmoud; John F Woolley; Ala-Eddin Al Moustafa; Mohammed Imad Malki
Journal:  Cancers (Basel)       Date:  2020-04-23       Impact factor: 6.639

4.  Amplification of Stem Genes: New Potential Metastatic Makers in Patients with an Early Form of Breast Cancer.

Authors:  Matvey M Tsyganov; Marina K Ibragimova; Alina M Pevzner; Artem V Doroshenko; Elena M Slonimskaya; Nikolai V Litviakov
Journal:  J Korean Med Sci       Date:  2019-12-23       Impact factor: 2.153

5.  Microarray Analysis of Gene Expression Involved in Butyrate-Resistant Colorectal Carcinoma HCT116 Cells.

Authors:  Chakkraphong Khonthun; Nongluk Saikachain; Siam Popluechai; Kongkiat Kespechara; Art Hiranyakas; Metawee Srikummool; Damratsamon Surangkul
Journal:  Asian Pac J Cancer Prev       Date:  2020-06-01

6.  Doxorubicin treatment modulates chemoresistance and affects the cell cycle in two canine mammary tumour cell lines.

Authors:  Michela Levi; Roberta Salaroli; Federico Parenti; Raffaella De Maria; Augusta Zannoni; Chiara Bernardini; Cecilia Gola; Antonio Brocco; Asia Marangio; Cinzia Benazzi; Luisa Vera Muscatello; Barbara Brunetti; Monica Forni; Giuseppe Sarli
Journal:  BMC Vet Res       Date:  2021-01-18       Impact factor: 2.741

7.  Precision Medicine for the Management of Therapy Refractory Colorectal Cancer.

Authors:  Hossein Taghizadeh; Robert M Mader; Leonhard Müllauer; Friedrich Erhart; Alexandra Kautzky-Willer; Gerald W Prager
Journal:  J Pers Med       Date:  2020-12-11

8.  Amplifications of Stemness Gene Loci-New Markers for the Determination of the Need for Neoadjuvant Chemotherapy for Patients with Breast Cancer. A Prospective Study.

Authors:  Nikolai V Litviakov; Marina K Ibragimova; Matvey M Tsyganov; Polina V Kazantseva; Artem V Doroshenko; Eugeniy Yu Garbukov; Irina G Frolova; Elena M Slonimskaya
Journal:  J Pers Med       Date:  2021-05-11

9.  Mutant-allele tumor heterogeneity in malignant glioma effectively predicts neoplastic recurrence.

Authors:  Pengfei Wu; Wei Yang; Jianxing Ma; Jingyu Zhang; Maojun Liao; Lunshan Xu; Minhui Xu; Liang Yi
Journal:  Oncol Lett       Date:  2019-10-11       Impact factor: 2.967

10.  Computationally predicting clinical drug combination efficacy with cancer cell line screens and independent drug action.

Authors:  Alexander Ling; R Stephanie Huang
Journal:  Nat Commun       Date:  2020-11-17       Impact factor: 14.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.